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a b s t r a c t
Aim: The myasthenia gravis-quality of life questionnaire 15 item (MG-QOL15) is a short, and
easy to use disease-speciﬁc quality of life (QOL) tool in myasthenia gravis. The aim of this
study was to validate and adapt the Polish version of the MG-QOL15.
Materials and methods: The total number of 50 patients with MG were qualiﬁed for the
examination. Each patient underwent neurological examination and completed the quality
of life evaluation questionnaire MQ-QOL 15 after translation and back-translation. Addi-
tionally, each patient was asked to evaluate the quality of his/her life by means of ques-
tionnaire SF-36 in Polish language version.
Results: The MG-QOL15 was found to have high internal consistency, test–retest reliability,
and concurrent validity.
Conclusion: The MG-QOL15 is accepted to be a valid, reliable, valuable tool for measuring
disease-speciﬁc QOL in Polish patients with MG.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/pjnns1. Introduction
Myasthenia gravis (MG) jest acquired autoimmune disease, the
basic pathomechanism of which is based on production of
auto antibodies directed against acetylocholine receptors
(anti-AchR) of post-synaptic membrane of neuromuscular
junction. The major symptom of MG is progressive myasthe-
nia, for which the following are typical: symptoms of
apocamnosis of extremities muscles and facial mimetic* Corresponding author at: Department of Neurology, Medical Univers
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http://dx.doi.org/10.1016/j.pjnns.2017.05.003
0028-3843/© 2017 Polish Neurological Society. Published by Elsevier Smuscles, diplopia, eyelid dropping, dysphagia, dyzarthria
[1,2]. Myasthenia gravis is characterized by big diversity of
its course. Some patients complain about numerous clinical
symptoms, which to a smaller or bigger extent make everyday
functioning difﬁcult, however, the majority of patients remain
in the disease remission period due to the applied treatment.
The remission condition is often not a condition without
occurrence of neurological symptoms [3]. Even small MG
symptoms may cause deterioration of the patients' life quality
by inﬂuencing both their private and professional lives. Theity of Silesia, ul. 3-go Maja 13-15, 41-800 Zabrze, Poland.
@sum.edu.pl (I. Rozmilowska).
p. z o.o. All rights reserved.
Table 1 – Demographic and clinical characteristic of
patients enrolled into the study.
Patients with myasthenia gravis (n) 50
Myasthenia character:
Ocular (%) 48
Generalized (%) 52
Mean age (years) 60.66  12.41
Average age (years) 30–81
Mean duration of disease (years) 9.48
Average of disease (years) 0.5–34
Gender:
Female (%) 56
Male (%) 44
Mean antibodies against rec. Ach (nmol/l) 8.79
Average antibodies against rec. Ach (nmol/l) 0.1–85
Thymoma (%) 10
Residual thymus (%) 56
Tymectomia (%) 58
Electrical activity in repetitive nerve stimulation (%) 86
Treatment:
Anticholinesterase drugs (%) 98
Steroids (%) 16
Azathioprine (%) 6
Mean doses of anticholinesterase drugs
(mg per day)
197.8
Mean BMI 24.96
Average BMI 21.15–32.75
Main neurological symptoms:
Diplopy (%) 44
Eyelids drooping (%) 72
Difﬁculty chewing (%) 10
Dysphagia (%) 16
Dysarthria (%) 20
Dyspnoea (%) 4
Apokamnosis symptoms of limbs and
mimetics muscles (%)
40
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 3 1 1 – 3 1 8312evaluation of the quality of life can be conducted using
questionnaire MG-QOL 15 (MG – quality of life 15) [4]. The
obtained results together with the assessment of neurological
condition provide a possibility of holistic approach to a patient,
and thus applying a more efﬁcient therapy.
In our paper we want to present the obtained results of
validation of the quality of life evaluation scale MG-QOL 15 of
patients with myasthenia gravis, conducted on Polish popula-
tion.
2. Materials and methods
2.1. Patients
The examination was conducted in Clinic of Neurology in years
2015–2016. The criteria of inclusion covered patients with
diagnosed myasthenia gravis (ocular and generalized) con-
ﬁrmed by neurological examination and on the grounds of
assessment: presence of antibodies against acetylocholine
receptors, electro physiological examinations (electrostimula-
tion and single-ﬁbre electromyography studies), neuroimage
examinations results (mediastinum MR or TK). The group was
representative as regards age and gender. The speciﬁc
characteristics of patients covered by the examination were
presented in Table 1.
The total number of 50 patients with MG were qualiﬁed for
the examination. Each patient underwent neurological
examination and completed the quality of life evaluation
questionnaire MQ-QOL 15 [4]. Additionally, each patient was
asked to evaluate the quality of his/her life by means of
questionnaire SF-36 in Polish language version [5,6]. For
reliability assessment (test–retest) all the examined persons
were asked to complete questionnaire MG-QOL 15 again
during the follow-up visit after four weeks. The examined
patients were qualiﬁed to selected groups in MGFA classiﬁca-
tion depending on the neurological evaluation of their
condition [7]. The work described in this article has been
carried out in accordance with the Code of Ethics of the World
Medical Association (Declaration of Helsinki) for experiments
involving humans No. KNW/0022/KB1/68/15; uniform
requirements for manuscripts submitted to biomedical
journals. Each patient expressed a written consent to
participation in the research.
2.2. Adaptation procedure questionnaire MG-QOL 15
Before the initiation of the validation process we obtained a
permission from the author's scale to conduct translation and
examinations using questionnaire. The MG-QOL 15 question-
naire was prepared in the USA by Professor Ted Burns et al. in
2008 on the grounds of myasthenia gravis (MG)-speciﬁc
quality-of-life (QOL). Instrument was reduced from 60 items
to 15 items while maintaining potential usefulness in the clinic
and in prospective treatment trials. The quality of life
evaluation form MG-QOL 15 consists of 15 questions. Each
question is assigned from 0 to 4 points, the maximum number
of obtainable points is 60. The particular questions constitute
the evaluation of physical, emotional, social functioning as
well as inﬂuence on professional and family life and pleasures.The higher the score of the examination the worse the patient
perceives the quality of his/her life [4,8].
In conformity with the requirements double translation
from English to Polish and again to English was made. The
translation was made by two bilingual teachers (Polish and
English languages) in collaboration with Polish medical
doctors ﬂuent in spoken and written English. Two indepen-
dent versions of translation of the original version of MG-QOL
15 were created and on their grounds the discrepancies were
corrected, with particular interest in grammatical and linguis-
tic conditionings. Finally, a Polish language version of
questionnaire MG-QOL 15 was obtained, the content of which
preserved the original meaning. The next stage was to
retranslate or translate again the newly obtained scale back
into the original language by a translator whose native
language is English but who is also ﬂuent in Polish. The Polish
version form prepared in the above manner was subjected to
evaluation of linguistic correctness by having it completed by
healthy Polish language speakers. The questionnaire was
completed by 30 persons, who were a representative group in
the aspect of gender, age and education. This procedure
allowed the conﬁrmation of proper linguistic construction
necessary to understand the questions correctly.
In the next stage 50 patients again completed questionnaire
MG-QOL 15 during the follow-up visit after 4 weeks from the
Fig. 1 – MQ-QOL 15 questionnarie in the Polish language version after the translation process.
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duced in the patients' therapy. The interval between the
examinations was long enough to eliminate the possibility
that the patients remembered the results chosen during the
previous evaluation. No irregularities were found in the results
obtained.
Fig. 1 presents the Polish language version of questionnaire
MG-QOl 15.
During the ﬁrst examination each patient was additionally
asked to complete life quality evaluation questionnaire SF-36
in Polish language version prepared by Prof. J. Tylka. It consists
of eleven questions evaluating: physical functioning, role
limitations due to physical health problems, bodily pain, social
functioning, general mental health, role limitations due to
emotional problems, vitality, general health perception. The
comprehensive summary enables a complex evaluation of
physical and emotional aspect of life. An additional parameter
evaluated in the questionnaire is a change of health condition
over a period of time. Interpreting the results: higher number
of points means lower grade in life quality evaluation [5,6].
The last element on our examination was neurological
assessment of patients conducted by the same examiner. A
full neurological examination was conducted on the grounds
of which each patient was qualiﬁed to an adequate class of
Myasthenia Gravis Foundation of America clinical classiﬁca-
tion (MGFA). Class I is mild in nature, Classes II, III and IV maybe further subdivided into category 'a', which primarily
impacts the limbs, or 'b', which primarily affects the
respiratory muscles or those of the tongue or mouth. Class
V is the most severe form requiring intubation. Table 2 showed
complete MGFA Clinical Classiﬁcation [7].
2.3. Statistical analysis
For data processing elements of descriptive statistics were
used, such as a geometric mean, median, standard deviation,
percentage distribution, variances. The evaluation of internal
coherence of test MG QOL 15 in Polish language version was
conducted using Cronbach's analysis. Cronbach's alpha raw
and standardized coefﬁcients were calculated. The coherence
level deﬁned by values of standardized alpha statistics >0.80
were considered satisfying. By analyzing a potential improve-
ment of alpha value after possible removal of successive
questions the inﬂuence of particular questions on the
coherence level was determined.
Evaluation of external conformity or internal conformity
assessment of a tool the relation of results obtained from
questionnaire MG-QOL 15 was analyzed with the results
obtained from the application of a different tool for life quality
assessment – questionnaire SF-36. Pearson and Spearman's
correlation coefﬁcient and statistical signiﬁcance the obtained
result were calculated. The reliability of the method was
Table 2 – MGFA clinical classification.
Class I Any ocular muscle weakness; may have weakness of eye closure. All other muscle strength is normal.
Class II a Mild weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting limb, axial muscles, or both.
Class II b Mild weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting oropharyngeal, respiratory muscles, or both.
Class III a Moderate weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting limb, axial muscles, or both.
Class III b Moderate weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting oropharyngeal, respiratory muscles, or both.
Class IV a Severe weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting limb, axial muscles, or both.
Class IV b Severe weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
Predominantly affecting oropharyngeal, respiratory muscles, or both.
Class V Deﬁned as intubation, with or without mechanical ventilation, except when employed during routine postoperative
management. The use of a feeding tube without intubation places the patient in class IV b.
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was estimated from the reliability coefﬁcient and the 95%
conﬁdence interval. Concurrent validity between scales at
each visit was estimated from the Pearson and Spearman
correlation coefﬁcients. The correlations obtained in all cases
were almost equal. The examination results were processed
on the grounds of statistical analysis using programmes
STATISTICA Data Miner 12.5 PL and EXCEL.
3. Results
The examination included the total number of 50 patients.
Their average age was 60.7, of which 56% were women, and
44% men, whereas the average time of the disease was
approximately 9 years. The distribution of patients according
to classiﬁcation MGFA was the following: 38% Class I (ocular),
20% Class II (mild, general), 14% in Class III (moderate, general),
6% Class IV (severe, general). In total 22% patients were in a
state of remission after visit 1. None of the examined persons
was intubated or ventilated (class V).
A total of 86% of patients were acetylcholine receptor
antibody positive (AChR+) and 14% of patients were negativeTable 3 – Percentage results received for particular questions q
N = 50 patients 
Questions 
1. I am frustrated by my MG 
2. I have trouble using my eyes 
3. I have trouble eating because of MG 
4. I have limited my social activity because of my MG 
5. My MG limits my ability to enjoy hobbies and fun activities 
6. I have trouble meeting the needs of my family because of my MG 
7. I have to make plans around my MG 
8. My occupational skills and job status have been negatively affected by
9. I have difﬁculty speaking due to MG 
10. I have trouble driving due to MG 
11. I am depressed about my MG 
12. I have trouble walking due to MG 
13. I have trouble getting around public places because of my MG 
14. I feel overwhelmed by my MG 
15. I have trouble performing my personal grooming needs (AchR). Main therapy of patients was based on anticholines-
terase drugs: a total of 98% received it. 78% of patients received
anticholinesterase drugs in doses below 240 mg per day and
22% of patients – equal or above 240 mg per day. Patients in a
state of remission were without neurological symptoms in ﬁrst
visit and during gradual reduction of doses anticholinesterase
drugs. All patients included into the study were presented
neurological symptoms at diagnosis (retrospective analysis
was prepared on the basis of medical documentation).
The average evaluation of life quality of the patients using
questionnaire MG-QOL 15 was 13.38 (SD  11.9), with mini-
mum obtained number of points 0 and maximum – 47. Table 3
presents percentage results received for particular questions.
The analysis of questionnaire reliability on the grounds of
statistical properties of test items and connections of
particular items with the overall test result demonstrated
Cronbach's raw coefﬁcient on level 0.952 point, whereas the
standard coefﬁcient was 0.948 point. The values of Cronbach's
alpha coefﬁcient for all particular items were over 0.80 point,
and a possible removal of a certain question from the
questionnaire did not cause a signiﬁcant change in the total
analysis. The lowest coherence was observed for questions 1, 7
and 9, and the highest for questions 4, 6 and 12. Table 4uestionnarie MG-QOL 15.
Answers (%)
Not at
all (0)
A little
bit (1)
Somewhat
(2)
Quite a
bit (3)
Very
much (4)
36% 48% 12% 4% 0%
26% 28% 36% 4% 6%
62% 18% 14% 4% 2%
46% 30% 14% 10% 0%
32% 28% 24% 14% 2%
62% 20% 12% 6% 0%
34% 32% 16% 16% 2%
 MG 18% 34% 18% 18% 12%
62% 22% 14% 2% 0%
40% 30% 12% 14% 4%
58% 26% 14% 2% 0%
56% 22% 10% 8% 4%
70% 16% 2% 8% 4%
48% 40% 10% 2% 0%
56% 34% 4% 6% 0%
Table 4 – Changes in the value of Cronbach alpha after the
removal of the following questions of questionnarie.
N = 50 patients Cronbach's alpha
evaluation
Questions
1. I am frustrated by my MG 0.887
2. I have trouble using my eyes 0.955
3. I have trouble eating because of MG 0.920
4. I have limited my social activity
because of my MG
0.959
5. My MG limits my ability to enjoy
hobbies and fun activities
0.917
6. I have trouble meeting the needs of
my family because of my MG
0.962
7. I have to make plans around my MG 0.879
8. My occupational skills and job status
have been negatively affected by MG
0.954
9. I have difﬁculty speaking due to MG 0.892
10. I have trouble driving due to MG 0.954
11. I am depressed about my MG 0.957
12. I have trouble walking due to MG 0.958
13. I have trouble getting around public
places because of my MG
0.953
14. I feel overwhelmed by my MG 0.954
15. I have trouble performing my
personal grooming needs
0.955
Diagram 2 – Correlation diagram questionnarie MG-QOL 15
with physical quality of life SF-36.
Diagram 3 – Correlation diagram questionnarie MG-QOL 15
with mental quality of life SF-36.
Diagram 4 – Correlation diagram questionnarie MG-QOL 15
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on general coherence level of questionnaire MG-QOL 15.
The comparison of summary results in questionnaire MG-
QOL 15 showed a positive correlation with results of
questionnaire SF-36 r = 0.92 point. It is a statistically signiﬁcant
result on level p < 0.001. Moreover, MG-QOL 15 showed a
positive correlation with the evaluation of functioning in a
physical aspect of scale SF-36 r = 0.93 point ( p < 0.001) and a
positive correlation in comparison with the mental aspect of
scale SF-36 r = 0.78 point ( p < 0.0001).
Additionally, the results of life quality evaluation obtained
from questionnaire MG-QOL 15 were analyzed and SF-36 with
current neurological condition of the examined patients
summed up in classiﬁcation MGFA. The obtained results
demonstrated the presence of positive correlation both of form
MG-QOL 15 with MGFA, where r = 0.85 ( p < 0.0001) and SF-36
with MGFA respectively r = 0.88 ( p < 0.0001). The above
described correlations were presented in Diagrams 1–5.Diagram 1 – Correlation diagram questionnarie MG-QOL 15
with questionnarie SF-36.
with neurological scale MGFA.The sensitivity and speciﬁcity of MG-QOL15 were assessed
depending on various threshold values. For the needs of this
research the so-called ‘‘golden standard’’ was considered the
assessment of clinical condition of patients using classiﬁca-
tion MGFA. It was determined that patients qualiﬁed to group
MGFA 0 – MGFA 2b in neurological assessment do not have
symptoms or have poorly intensiﬁed symptoms – mild course
of the disease. The patients qualiﬁed to class MGFA 3a – MGFA
5 are people with bigger or much bigger intensiﬁcation of
symptoms – severe course of disease. With reference to results
of the quality of life assessment, the patients qualiﬁed to the
ﬁrst group under MGFA classiﬁcation showed high evaluation
Diagram 5 – Correlation diagram questionnarie SF-36 with neurological scale MGF.
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low evaluation of their lives quality. We analyzed in details the
results of MQ QOL 15 assessment conducted among patients
with regards to MGFA classiﬁcation. The cut-off point,
determined in our validation examination MG QOL 15,
equalling 15 points, in examination of Polish population of
patients allowed for adequate classiﬁcation of 89% of exam-
ined people – 94% persons assessing their lives quality as high
and 84% persons with law assessment of their quality of lives.
The result equalling 12 points allowed for classiﬁcation in
conformity with the speciﬁc scheme the total number of 81%
patients, of which 99% persons with high assessment of
quality of life and only 67% with low. The result which equals
18 points involves a slight increase of the scale sensitivity to
98% and decrease of speciﬁcity to 78% (total number of 87%
adequate classiﬁcations). The analysis of ROC curve conﬁrmed
very good differentiating properties of MG QOL 15 (ﬁeld under
the curve equals 0.84; p < 0.001). Graph 6 shows ROC curve for
MG QOL 15.
The test-rest method conducted on the grounds of analysis
of the obtained results in an interval up to 4 weeks
demonstrated high reliability of measurement in the aspect
of stability of result in time, rtt = 0.89, p < 0.001. The highest
ICC values were discovered for questions 2, 4 and 6 andGraph 6 – Receiver operating characteristic (ROC) curve of
MG-QOL 15. Cut point = 15.00.questions 10–14, whereas the lowest ICC value was observed
for questions 7 and 9.
4. Discussion
On the grounds of obtained results it may be stated that
questionnaire MG-QOL 15 is a reliable tool for assessment of the
quality of life of patients with myasthenia gravis in Polish
population. The patients considered it clear and useful in overall
assessment of their health condition. The high reliability of the
questionnaire is proved by satisfactory values of Cronbach's
alpha coefﬁcients (above 0.80 point) comparable to the English
version of the questionnaire. The value of individual, both raw
and standarized Cronbach's alpha coefﬁcients do not suggest a
necessity to remove any question. In addition, and important
element is the fact that the values of raw and standarized
Cronbach's alpha coefﬁcients are very similar.
The test–retest assessment conﬁrmed the questionnaire's
reliability, no statistically signiﬁcant differences were found
for measurements conducted twice in a certain time interval.
Despite the above we did not manage to discover the reason of
low ICC values on two items. The speciﬁc course of the disease,
in which the patients may feel greater tiredness as the day
passes by, in combination with infection, stress or physical
effort may affect the quality of life assessment. Thus, the
continuous feeling of fatigue has inﬂuence on the question-
naire results and their repetitiveness may be disturbed despite
preserving the neurological examination and treatment
continuity. The existence of such dependencies suggests
completion of the questionnaire at the same time of the day
and in uniform time intervals taking into consideration factors
affecting the course of the disease.
The validity assessment of questionnaire MG-QOL 15 was
conﬁrmed by correlating the results with answers obtained in
another important tool for the quality of life assessment –
questionnaire SF-36. The patients who obtained more points
in MG-QOL 15, i.e. their assessment of life quality was worse,
also in SF-36 obtained high values. A positive correlation was
observed both in mental and physical aspect. A positive
correlation was conﬁrmed with reference to neurological
condition assessed on the grounds of MGFA classiﬁcation.
Intensiﬁcation of neurological symptoms, and in particular the
presence of symptoms of limbs fatigability (MGFA II b, MGFA III
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higher number of points obtained in questionnaire MG-QOL 15.
The purpose of our research was to, ﬁrst of all, adapt the
scale of assessment of quality of life MG-QOL15 for patients
with a certain disease, namely myasthenia gravis. We
analyzed the factors which could inﬂuence the research
result. Almost all patients, 98%, were undergoing therapy
with anticholinesterase inhibitors, which was not modiﬁed in
the last month. We did not include in the research patients
classiﬁed as MGFA V class, because there was no possibility of
cooperation and it would be difﬁcult to complete the life
quality assessment questionnaire. Patients with symptoms of
infections had appointments for different dates of examina-
tions. However, our assumptions did not include the inﬂuence
of many factors, for example such as suffered myasthenic
crisis, exacerbations of the disease requiring steroid therapy,
thymectomy surgery, etc. we wanted to adjust the tool of work
with patients in Polish population, and the above dependen-
cies will be the subject of further research. The limitation is
certainly the size of the examined group, nevertheless the
frequency with which myasthenia gravis occurs in Polish
population (10–15 persons per 100,000 population) induced us
to assess the group of patients who remain under our care.
Questionnaire MG-QOL 15 is used to assess the quality of life
of patients with myasthenia gravis in many countries. The
validations conducted in such countries as Japan, Turkey or Iraq
showed high internal reliability, repetitiveness in test–retest
assessment and at the same time validity with SF-36 and the
disease intensiﬁcation determined by MGFA. The advantage of
research on Japanese or Persian population is a bigger size group
(327 and 75 persons respectively). Despite the above, our research
demonstrated equally high and satisfying results of statistical
analysis – internal consistency (Cronbach alpha = 0.952) and test
–retest reliability (rtt = 0.89; p < 000.1) [9–11].
The practical application of scale MG-QOL 15 conﬁrmed the
prospective assessment of efﬁciency of treatment with
mycophenolate mofetil conducted by Mullins et al. in patients
with myasthenia gravis. The comparison showed that MG-
QOL 15 demonstrates more signiﬁcant results that the quality
of life assessment made by questionnaire SF-36, to conﬁrm
changes in the disease course after applied treatment. The
results of this research supported the application of this tool
for assessment of life quality both clinically and in trials of new
treatment for myasthenia gravis [12]. An application similar to
the ﬁnal point of assessment of efﬁciency of treatment of
patients with myasthenia gravis after plasmapheresis treat-
ments vs treatments with immunoglobulins was used by
Barnett et al. in their research. His research also conﬁrmed the
correctness of application of scale MG-QOL 15 as a reliable tool
in clinical research [13].
With reference to the discussion on reliability and
relevance of questionnaire MG-QOL 15 the latest reports
published in June 2016 by the author of the scale are
signiﬁcant. In his research, Burn et al. having analyzed over
1300 cases of patients suffering from myasthenia gravis in the
aspect of life quality assessment, came to the conclusion that
scale MG-QOL 15 has better clinimetric properties when
applying 3 instead of 5 answers. In a new version the patients
can choose from the following answers: ‘‘not at all’’,
‘‘somewhat’’ and ‘‘very much’’. MG-QOL15r is now a preferredinstrument of life quality assessment for patients with
myasthenia gravis. This change does not deny previously
conducted research [14].
5. Summary
The evaluation of quality of life has an important role in
holistic care of a patient. It provides us with information about
how a patient perceives the degree of disability, difﬁculties in
social, professional and family functioning. Moreover, it shows
to what extent the patient accepts his/her health condition.
MG-QOL 15 was designed and veriﬁed in order to be used in
clinical and research practice in an intelligible way. We created
a Polish language version of MG-QOL 15 conﬁrming its
reliability and credibility. We are aware about the limitation
of our research what is the number of patients qualiﬁed for
study. Further studies concerning the assessment of the
quality of life among patients with myasthenia are planning.
Thus, to sum up, MG-QOL 15 may be considered a suitable
instrument for evaluation of physical, mental and social
aspects of life of patients with myasthenia gravis.
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